EPRX · Eupraxia Pharmaceuticals Inc
United States · RS rating 40 · As of 2026-10-14
| Price | 6.59 USD |
|---|---|
| 1-day change | -1.4% |
| RS rating (overall / 1M / 3M / 12M) | 40 / 12 / 82 / 59 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 27 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +27.6% |
| Market cap (USD) | $445.9M |